Advertisement
Canada markets closed

  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • CAD/USD

    0.7282
    -0.0005 (-0.06%)
     

  • CRUDE OIL

    78.32
    -0.06 (-0.08%)
     

  • Bitcoin CAD

    85,648.10
    -1,100.16 (-1.27%)
     

  • CMC Crypto 200

    1,296.09
    -69.03 (-5.06%)
     

  • GOLD FUTURES

    2,323.10
    -1.10 (-0.05%)
     

  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • NASDAQ futures

    18,203.00
    +3.50 (+0.02%)
     

  • VOLATILITY

    13.23
    -0.26 (-1.93%)
     

  • FTSE

    8,313.67
    +100.18 (+1.22%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6770
    -0.0001 (-0.01%)
     

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

Cingulate Inc.
·1 min read
Cingulate Inc.
Cingulate Inc.

KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST. The appearance had previously been scheduled for Friday December 2, 2022, at 10:00 a.m. CST.

The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

ADVERTISEMENT

About Cingulate® 
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton 
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805